Price Discrimination Across Indications in the Pharmaceutical Industry: The Case of Finasteride

Başlevent, Cem
This paper examines the price differential between two prescription drugs (Proscar and Propecia) which contain the same active ingredient (finasteride) in different dosages. It is argued that the price differential is an example of price discrimination across indications of the same substance.


Nanocrystal Encoded FluorescentMicrobeads for Proteomics AntibodyProfiling and Diagnostics ofAutoimmune Diseases
Sukhanova, Alyona; Susha , Andrei; Bek, Alpan; Mayilo, Sergiy; Rogach , Andrey; Feldmann, Jochen; Oleinikov, Vladimir; Reveil, Brigitte; Donvito, Beatrice; Cohen, Jacques; Nabiev, İgor (2007-01-01)
The first application of nanocrystal (NC)-encoded microbeads to clinical proteomics is demonstrated by multiplexed detection of circulating autoantibodies, markers of systemic sclerosis. Two-color complexes, consisting of NC-encoded, antigen-covered beads, anti-antigen antibody or clinical serum samples, and dye-tagged detecting antibodies, were observed using flow cytometry assays and on the surface of single beads. The results of flow cytometry assays correlated with the ELISA technique and provided clear...
Metformin – Cisplatin Combination Treatment Alters mRNA Expression of Hexokinase II Gene in LNCaP and PC3 Prostate Cancer Cell Lines
Durukan, Özlem; Evin, Emre; Arslan, Şevki; Adalı, Orhan (null; 2017-07-08)
Metformin is an antidiabetic drug with anticancer properties. Cisplatin is known as one of the most potent chemotherapeutics for treatment of various types of cancer. In order to overcome cisplatin resistance and toxicity, the drug can be combined with other chemotherapeutics that sensitize tumour cells to cisplatin. The ability of metformin to potentiate cisplatin-mediated killing of cancer cells in vitro, makes it a plausible candidate for combination with cisplatin-based therapy. The aim of this study is...
Squaramide catalyzed alpha-chiral amine synthesis
Karahan, SEDA; Tanyeli, Cihangir (2018-10-17)
Enantiomerically pure alpha-chiral amines, have been commonly utilized as resolving agents and chiral auxiliaries and are currently found in 40% of active pharmaceutical ingredients. Hence, development of highly stereoselective metal-free protocols regarding atom-economy and large-scale applications becomes a major issue. In this respect, chiral bifunctional H-bonding squaramides have been successfully applied for both amine synthesis and functionalization of amines in the last decade. This survey summarize...
pH responsive release of curcumin from photocrosslinked pectin/gelatin hydrogel wound dressings
Bostancı, Nazlı Seray; Büyüksungur, Senem; Hasırcı, Nesrin; Tezcaner, Ayşen (2022-01-01)
© 2022 Elsevier B.V.The aim of this study was to develop hydrogel wound dressings made of photocrosslinkable pectin and gelatin with pH dependent release of curcumin, an antimicrobial agent. Methacrylated forms of pectin and gelatin (PeMA and GelMA, respectively) were synthesized, and hydrogels were prepared with different compositions (1:1, 1:2 and 1:3 v/v ratios of PeMA and GelMA) by UV exposure. Pure GelMA was used as control group. Average pore diameter of hydrogels with the highest PeMA content (P1:G1)...
Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
Ture, Asli; Kahraman, Deniz Cansen; Atalay, Rengül; Helvacioglu, Sinem; Charehsaz, Mohammad; KÜÇÜKGÜZEL, İLKAY (2019-02-01)
Thirty-two novel urea/thiourea compounds as potential kinase inhibitor were designed, synthesized and evaluated for their cytotoxic activity on breast (MCF7), colon (HCT116) and liver (Huh7) cancer cell lines. Compounds 10, 19 and 30 possessing anticancer activity with IC50 values of 0.9, 0.8 and 1.6 mu M respectively on Huh7 cells were selected for further studies. These hit compounds were tested against liver carcinoma panel. Real time cell electronic sensing assay was used to evaluate the effects of the ...
Citation Formats
C. Başlevent, “Price Discrimination Across Indications in the Pharmaceutical Industry: The Case of Finasteride,” ODTÜ Gelişme Dergisi, vol. 33, no. 1, pp. 155–160, 2006, Accessed: 00, 2020. [Online]. Available: